Drug Updates

Update on drugs, approval dates, and comments. Calcipotriene/Calcipotriol0.005% foam (Sorilux™), Ceftaroline fosamil (Teflaro™) are covered as well as an update on Health Canada on the use of tacrolimus (Protopic®) for atopic dermatitis.

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

October 2010: Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®), and recent news with Health Canada.

Update on drugs, approval dates, and comments. Velaglucerase alfa (VPRIV®) and Health Canada labelling changes for isopropyl myristate 50% rinse (Resultz®, Nycomed) to include the treatment of lice in children =2 years of age are covered.

Update on drugs, approval dates, and comments. Belimumab (Benlysta®), Adapalene 0.1% gel, Antiseborrheic compound (K301/Kaprolac®) are covered.

Update on CD56-binding monoclonal antibody (huN901) + maytansinoid cytotoxic agent (DM1) IMGN901, Small molecule oxychlorine compound (Microcyn® Skin and Wound HydroGel), Antifungal agent (K101/Kaprolac®).

Update on drugs, approval dates, and comments. Imiquimod 3.75% cream (Zyclara™), Adapalene 0.1% lotion (Differin®), Polidocanol injection (Asclera®) are covered.

Update on drugs, approval dates, and comments. Collagenase clostridium histolyticum (XIAFLEX™), HPV quadrivalent recombinant vaccine (Gardasil®), Velaglucerase alfa (VPRIV™), Agalsidase alfa (REPLAGAL®), Adalimumab (Humira®) are covered.

Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).

Update on Imiquimod 3.75% Cream Zyclara™, Acyclovir + Hydrocortisone Cream Xerclear®/Lipsovir®, as well as drug news on Titanium dioxide (TiO2).

Update on Capsaicin 8% Patch Qutenza™, Alitretinoin Capsule Toctino® as well as news about a recent study by Kenter et al.* explored the efficacy of a human papillomavirus (HPV) vaccine.

Updates on Ustekinumab Stelara® Centocor Ortho Biotech, Romidepsin ISTODAX® Gloucester Pharmaceuticals and news from US FDA.

Update on Collagen-based dermal filler Evolence®, Injectable Poly-L-lactic acid Sculptra Aesthetic®, Ibritumomab tiuxetan Zevalin®, and news from US FDA on TNF blockers.

Update on Benzyl Alcohol Lotion 5% Sciele Pharma, Red Light Technology Device + Methyl Aminolevulinate Cream Aktilite® CL 128 + Metvix®, and news Nexavar®.

Update on Golimumab (Simponi™) Centocor/Schering-Plough, Darunavir (PREZISTA™) Tibotec/Janssen-Ortho, Telavancin (Arbelic™) Theravance/Astellas, and news from US FDA.

Update on Alitretinion (Toctino®), Pralatrexate, Benzyl Alcohol Lotion 5%, and Botulinum Toxin – Type A (Azzalure®) and news on Efalizumab (Raptiva®).

Update on Ustekinumab Stelara®, Photopheresis System THERAKOS™ CELLEX™, Calcitriol Vectical™ Ointment, Autologous Collagen Cellular Processing System Isolagen Therapy™.

Update on Alitretinoin (Toctino®), Denileukin Diftitox (Ontak™), Bimatoprost Ophthalmic 0.03% Solution (LATISSE®), Maraviroc (SELZENTRY®), Clindamycin Phosphate 1.2% + Benzoyl Peroxide 2.5% (Acanya® Gel), Etanercept (Enbrel®).

Update on Ceftobiprole (Zeftera®) Johnson & Johnson/ Basilea Pharmaceuticals, IV Iclaprim Arpida Ltd., HPV Vaccine (Gardasil®) Merck & Co., Alitretinoin (Toctino®) Basilea Pharmaceuticals, and Atazanavir sulfate (REYATAZ®) Bristol-Myers Squibb.

Update on Bimatoprost Ophthalmic Solution 0.03% Lumigan®, Ustekinumab (CNTO-1275) Centocor, p53 tumor suppressor therapy ADVEXIN®, Shingles Vaccine Zostavax®, Calcipotriene 0.005% + betamethasone dipropionate 0.064% Xamiol® Gel, and Etanercept Enbrel®.

Update on Certolizumab pegol Cimzia® UCB S.A., Golimumab Centocor, Ceftobiprole medocaril ZEFTERA® Basilea Pharmaceuticals, and Tipranavir Aptivus® Boehringer-Ingelheim.

Update on Adapalene Differin® Gel 0.1%, Methyl Aminolevulinate Hydrochloride Cream Metvixia™ + Aktilite®, and Cross-linked Collagen EVOLENCE®.

Update on Calcipotriene 0.005% + Betamethasone Dipropionate 0.064% Topical Suspension (Taclonex Scalp®), Calcipotriene 0.005% Topical Solution, and Botulinum Toxin Type A (Reloxin®) and news about new drugs for acne and psoriasis.

Update on Triphendiol (formerly NV-196), Cyclic pentapeptide vascular-targeting agent ADH-1, Certolizumab pegol Cimzia® and drug news from around the world.

Update on Peginterferon alfa-2b PEG-Intron™, Elesclomol (formerly STA-4783), Hyaluronic Acid Gel + Lidocaine Prevelle Silk™.

Update on Anti-psoriatic Agent Adalimumab (Humira®), Antihistamine (Claritin®), HIV drug Etravirine (Intelence™) and news about new antioxidant, coffeeberry (REVALÉSKIN™, Stiefel Laboratories)

Update on Anti-psoriatic Agent Ustekinumab CNTO 1275, Anti-arthritic Agent Tocilizumab Actemra®, Neurotoxin Botulinum Toxin Type A Reloxin®, and news from The National Institute for Health and Clinical Excellence (NICE) in the UK.

Update on Loratadine Dry Syrup 1% Claritin® Schering-Plough, Valacyclovir Hydrochloride TEVA Pharmaceutical Industries, and news about Anti-dandruff, anti-acne and anti-melanoma agents.

Update on Terbinafine hydrochloride Lamisil® Novartis Pharmaceuticals, Famciclovir TEVA Pharmaceutical Industries, Ceftobiprole BAL5788 Basilea Pharmaceutica/Janssen-Ortho.

Update on Nanocrystalline Silver Cream NPI32101, Daptomycin for Injection CUBICIN®, Oral Alitretinoin BAL4079, Smallpox Vaccine ACAM2000, and news about new US FDA regulations.

Update on Adapalene Differin® Gel 0.3%, Adalimumab HUMIRA®, Hyaluronic Acid Injectable Soft Tissue Filler Cangene ELEVESS®, Ketoconazole Extina® Foam 2%.

Update on Hyaluronic Acid Gel Particles PERLANE®, Cervical Cancer Vaccine Cervarix®, Vaccinia Immune Globulin Intravenous (Human), Levocetirizine Dihydrochloride Xyzal®, and Infliximab Remicade®.

Update on Retapamulin Ointment 1% Altabax® GlaxoSmithKline, Quadrivalent Human Papillomavirus Recombinant Vaccine Gardasil® Merck, Quadrivalent Human Papillomavirus Recombinant Vaccine AERIUS®/ AZOMYR®/ NEOCLARITYN® Schering-Plough.

Update on Antiacne Agent Drospirenone/ Ethinyl Estradiol Yaz® Berlex, Corticosteroid Clobetasol Propionate 0.05% Olux-E™ Foam Stiefel Laboratories and news from US FDA.

Update on Antiacne Agent Drospirenone/ Ethinyl Estradiol Yaz® Berlex, Clobetasol Propionate 0.05% Olux-E™ Foam Stiefel Laboratories, and news from US FDA.

Update on Diclofenac Sodium 3% Gel Solaraze®, Retapamulin Ointment 1% Altabax™, Calcium Hydroxylapatite Microspheres in Water-based Gel Radiesse®, Rose Bengal Disodium 10% PV-10, and Taxane Potentiator STA-4783.

Update on Clindamycin Phosphate 1.2%/ Tretinoin 0.025% Ziana™ Gel, Adalimumab Humira®, Aminolevulinic Acid/ Light Levulan® Kerastick®, Oblimersen Sodium Injection Genasense™, and Epratuzumab LymphoCide™.

Update on Polymethylmethacrylate/ Bovine Collagen ArteFill® Artes Medical, Polyphenon® E Ointment 15% MediGene AG/ Bradley Pharmaceuticals, and drug news on melanoma and new vaccines.

Update on Ketoconazole 2% Gel Xolegel™, Infliximab Remicade®, Quadrivalent Human Papillomavirus Recombinant Vaccine Gardasil™, Desonide Verdeso™ Foam 0.05% and drug news about melanoma and anti-acne agents.

Update on Ketoconazole 2% Gel Xolegel™, Famciclovir Tablets Famvir®, Ecamsule 2% + Avobenzone 2%/ Octocrylene 10% Cream Anthelios SX®, and news about lice treatment.